Maze Therapeutics (NASDAQ:MAZE) Insider Atul Dandekar Sells 7,500 Shares of Company Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) insider Atul Dandekar sold 7,500 shares of the company’s stock in a transaction on Tuesday, September 29th. The shares were sold at an average price of $27.06, for a total transaction of $202,950.00. Following the sale, the insider owned 32,316 shares of the company’s stock, valued at $874,470.96. The trade was a 18.84% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Atul Dandekar also recently made the following trade(s):

• On Thursday, September 3rd, Atul Dandekar sold 3,243 shares of Maze Therapeutics stock. The stock was sold at an average price of $26.01, for a total value of $84,350.43.
• On Wednesday, September 2nd, Atul Dandekar sold 3,191 shares of Maze Therapeutics stock. The stock was sold at an average price of $26.47, for a total value of $84,465.77.
• On Friday, August 28th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The shares were sold at an average price of $27.58, for a total value of $206,850.00.
• On Wednesday, July 29th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The shares were sold at an average price of $27.34, for a total value of $205,050.00.

Maze Therapeutics Trading Down 1.9%

NASDAQ:MAZE traded down $0.53 during mid-day trading on Thursday, hitting $26.65. The company had a trading volume of 589,347 shares, compared to its average volume of 665,813. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31. Maze Therapeutics, Inc. has a fifty-two week low of $21.95 and a fifty-two week high of $53.65. The firm has a market cap of $1.48 billion, a P/E ratio of -10.58 and a beta of 2.17. The business’s fifty day moving average is $27.02 and its two-hundred day moving average is $28.40.

Maze Therapeutics (NASDAQ:MAZE) last posted its earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.76). As a group, research analysts expect that Maze Therapeutics, Inc. will post -2.72 earnings per share for the current year.

Wall Street Analyst Weigh In

MAZE has been the topic of several analyst reports. Wall Street Zen lowered shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. BTIG Research reissued a “buy” rating and issued a $46.00 price target on shares of Maze Therapeutics in a report on Tuesday, September 22nd. HC Wainwright restated a “buy” rating and issued a $110.00 price objective on shares of Maze Therapeutics in a research report on Thursday, September 24th. Wedbush reaffirmed an “outperform” rating and set a $48.00 price objective on shares of Maze Therapeutics in a research note on Wednesday, September 23rd. Finally, Citigroup assumed coverage on Maze Therapeutics in a report on Wednesday, September 23rd. They set a “buy” rating and a $50.00 target price on the stock. Three research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $63.40.

Institutional Trading of Maze Therapeutics

Large investors have recently bought and sold shares of the business. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in Maze Therapeutics in the second quarter valued at approximately $48,000. Royal Bank of Canada lifted its position in Maze Therapeutics by 214.1% in the 1st quarter. Royal Bank of Canada now owns 2,029 shares of the company’s stock valued at $61,000 after acquiring an additional 1,383 shares in the last quarter. Quantbot Technologies LP acquired a new position in Maze Therapeutics in the 2nd quarter worth $80,000. Caitong International Asset Management Co. Ltd acquired a new position in Maze Therapeutics in the 4th quarter worth $145,000. Finally, Persistent Asset Partners Ltd bought a new position in Maze Therapeutics during the 2nd quarter worth about $200,000.

Maze Therapeutics Company Profile

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically driven diseases. The company combines human genetics, functional genomics and drug discovery technologies through its Maze Compass platform to identify disease mechanisms and develop therapies designed to address the underlying causes of disease.

Maze’s lead program, MZE001, is an oral small-molecule inhibitor of glycogen synthase being developed for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles and other tissues.